Rosen Law Firm reminds SPRY shareholders of October 5 lead plaintiff deadline in securities fraud class action alleging misleading CVS Caremark formulary timeline for neffy
Executive summary: Rosen Law Firm published a PR Newswire alert reminding SPRY purchasers during the March 9–June 24, 2026 class period of the October 5, 2026 lead plaintiff deadline in a securities fraud class action. The suit centers on alleged misstatements about the CVS Caremark formulary effective date for neffy; the subsequent disclosure caused a 23.9% single-day drop, creating significant shareholder losses and potential liability for the company and its officers.
Who is involved: ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), Rosen Law Firm (plaintiffs' counsel), CVS Caremark, and investors who bought shares during the class period.
Likely next (inference): Lead plaintiff motions will be filed by October 5, 2026; the court will then appoint a lead plaintiff and counsel, after which discovery and motion practice will commence.
Rosen Law Firm has issued a reminder to investors who purchased ARS Pharmaceuticals (NASDAQ: SPRY) shares between March 9 and June 24, 2026, that the lead plaintiff deadline in the securities fraud class action is October 5, 2026. The lawsuit alleges the company misrepresented the timing of expanded CVS Caremark coverage for its epinephrine nasal spray neffy, which led to a 23.9% single-day share decline when the formulary date slipped from July 1, 2026 to January 2027. Multiple law firms have filed similar alerts since mid-August, indicating a coordinated plaintiff recruitment effort.
What's next — scenarios
Inference: scenarios and probabilities are Beyond's assessment, not reported fact.
Legal Victory / Dismissal (40%)
SPRY avoids long-term litigation overhang, allowing management to focus on commercialization of neffy.
- Judge denies motion to dismiss
- Lead plaintiff appointment is successful with minimal class size
Protracted Litigation / Settlement (45%)
Significant cash outflow for SPRY to settle claims, impacting R&D budget for future pipeline assets.
- Class certification granted
- Settlement negotiations announced
Adverse Regulatory/Coverage Delay (15%)
Further timeline slippage beyond January 2027 leads to secondary class action or investor exodus.
- CVS Caremark issues new formulary update
- SEC inquiry into disclosure timelines
What to watch
- October 5, 2026: Lead plaintiff filing deadline
- CVS Caremark January 2027 formulary status updates
- SPRY quarterly earnings call regarding litigation reserves
- SPRY market share data for neffy (next 90 days)
Timeline
- — SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit (PR Newswire)
- — SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY (PR Newswire)
- — Levi & Korsinsky Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY (PR Newswire)
- — SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact SueWallSt (PR Newswire)
- — INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY (PR Newswire)
- — SPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities Lawsuit - Contact Levi & Korsinsky (PR Newswire)
- — SPRY Shareholder Alert: ARS Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm (PR Newswire)
- — Robbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm (PR Newswire)
Analysis — what this means
Likely next events
- Lead plaintiff deadline: October 5, 2026 (per Rosen Law Firm alert).
- Court appointment of lead plaintiff and lead counsel shortly after deadline.
- Potential motion to dismiss by ARS Pharmaceuticals in Q4 2026.
Sectors affected
- Specialty pharmaceuticals
- Biotechnology
- Securities litigation
Regulatory implications
- Potential for parallel SEC enforcement if misstatements are deemed material.
Historical parallels
- Impax Laboratories (2017) – securities class action over generic drug pricing disclosures.
- Mylan (2017) – EpiPen pricing litigation and shareholder suits.
Contradictions
- Levi & Korsinsky (Aug 26) cites a 23.9% single-day share decline; SueWallSt (Aug 20) cites a $2.52 per share loss. Both refer to the same event but quantify the drop differently.
Key entities
Sources
- SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit — PR Newswire
- SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit — PR Newswire
- Robbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm — PR Newswire
- SPRY Shareholder Alert: ARS Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm — PR Newswire
- SPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities Lawsuit - Contact Levi & Korsinsky — PR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY — PR Newswire
- SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact SueWallSt — PR Newswire
- Levi & Korsinsky Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY — PR Newswire
- SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY — PR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY — PR Newswire
Related cases
- ARS Pharmaceuticals faces intensifying legal pressure as multiple law firms initiate securities fraud class actions
- ARS Pharmaceuticals faces intensified legal scrutiny amid multiple class action lawsuits over alleged securities fraud
- Securities class action lawsuit deadline approaching for ARS Pharmaceuticals investors
- ARS Pharmaceuticals faces critical deadline for investors seeking to lead securities fraud class action litigation
- Investors get chance to serve as lead plaintiffs in ARS Pharmaceuticals securities fraud lawsuit
- Rosen Law Firm launches a securities fraud class action against ARS Pharmaceuticals, exposing the company to potential legal costs and share‑price pressure